Also trades as: 0J9P.L (LSE) · $vol 0M
INCY NASDAQ
Incyte Corporation
1W: -0.0%
1M: -6.6%
3M: -8.3%
YTD: +15.0%
1Y: +27.7%
3Y: +111.5%
5Y: +78.1%
$116.60
+3.29 (+2.90%)
Weekly Expected Move ±4.1%
$106
$111
$116
$120
$125
Credit Risk of going bust: lower than 96% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Incyte Corporation would be worth roughly what it owes.
Total debt $38.3M against a stock market value of $22.97B.
Distance to default 21.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $19.1M (short-term plus half of long-term), stock volatility 33.5%; Altman Z'' 10.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Incyte Corporation would be worth roughly what it owes.
Total debt $38.3M against a stock market value of $22.97B.
Distance to default 21.13 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $19.1M (short-term plus half of long-term), stock volatility 33.5%; Altman Z'' 10.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.30
Neutral
0 bullish
4 neutral
2 bearish
Articles (7d)
6
Daily Sentiment (7 Days)
Articles (100)
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Genmab, Incyte team up to develop experimental colorectal cancer treatment
Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for
7,443 Incyte Corporation $INCY Shares Bought by Farther Finance Advisors LLC
Syndax plummets as IPF asset axatilimab fails in phase 2 trial
Notable healthcare headlines for the week: Novavax, Moderna and Becton Dickinson in focus
Stock futures rise after Nasdaq hits record high
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focus
9,703 Incyte Corporation $INCY Shares Acquired by CX Institutional
INCY or TECH: Which Is the Better Value Stock Right Now?
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
At a glance: stocks gapping up premarket
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
Stock futures edge higher as Hormuz reopening talks regain focus
Nykredit A S Makes New $4.68 Million Investment in Incyte Corporation $INCY
Specialised Therapeutics to commercialize Incyte’s Opzelura in Australia
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Bank of America Corp DE Invests $76.65 Million in Incyte Corporation $INCY
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Integrated Wealth Concepts LLC Sells 5,987 Shares of Incyte Corporation $INCY
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Stock futures rise as traders look ahead to wholesale inflation report
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
84,502 Shares in Incyte Corporation $INCY Bought by Beacon Pointe Advisors LLC
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
Stock futures mixed as investors look ahead to retail earnings
Stock index futures largely flat after S&P 500 closes at record high
Cetera Investment Advisers Has $2.40 Million Position in Incyte Corporation $INCY
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
REGN or INCY: Which Is the Better Value Stock Right Now?
Here's Why Incyte (INCY) is a Strong Momentum Stock
Here's Why Incyte (INCY) is a Strong Growth Stock
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Here's Why Incyte (INCY) is a Strong Value Stock
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
Incyte raises sales outlook as Opzelura, cancer portfolio fuel strong quarter
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Here are the major earnings before the open Tuesday
Entropy Technologies LP Grows Stock Holdings in Incyte Corporation $INCY
Dai ichi Life Insurance Company Ltd Boosts Stake in Incyte Corporation $INCY
Earnings week ahead: AAPL. MSFT, AMZN, META, XOM, PYPL, CVX, F, KO, ABBV, V, QCOM, BA, MO, SOFI, and more
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
HALO Inks Deal With INCY to Support Cancer Therapy Development
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Bank of New York Mellon Corp Trims Stock Position in Incyte Corporation $INCY
Fifth Third Bancorp Boosts Stock Position in Incyte Corporation $INCY
Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
2 Fast-Growing Pharmaceutical Stocks to Buy Now
Tesla, AMD, and SpaceX headline Cathie Wood's biggest H1 portfolio bets
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms
Acadia rises as EU backs Rett syndrome therapy
US stock futures mixed as mega-cap tech drags market sentiment
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP
Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more
Here's Why Incyte (INCY) is a Strong Value Stock
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Here's Why Incyte (INCY) is a Strong Growth Stock
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Here's Why Incyte (INCY) is a Strong Momentum Stock
Here's Why Incyte (INCY) is a Strong Value Stock
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Here's Why Incyte (INCY) is a Strong Growth Stock
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Company News for Apr 29, 2026
Incyte outlines $4.77B-$4.94B 2026 net sales while preparing four launches over 12 months
Incyte (INCY) Q1 2026 Earnings Call Transcript
Incyte (INCY) Q2 2025 Earnings Transcript
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales
Compared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key Metrics
Incyte taps Zimmer Biomet's Suketu Upadhyay as CFO
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Earnings Scheduled For April 28, 2026
Incyte Non-GAAP EPS of $1.81 beats by $0.47, revenue of $1.26B beats by $50M
Here are the major earnings before the open Tuesday